A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Trial Identifier: D822FC00008
Sponsor: AstraZeneca
Collaborator:
Acerta Pharma B.V
NCTID:: NCT04489797
Start Date: July 2020
Primary Completion Date: August 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version

Trial Locations

Country Location
United States of America, CA Anaheim, CA, United States of America, 92801